Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SMS001 as Adjuvant Therapy in Stage Ia-IIIa NSCLC
NCT06693336Phase 2Recruiting
- Sponsor
- ToLymph
- Start
- Nov 2024
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of paclitaxel in non-small cell lung cancer (NSCLC), sponsored by ToLymph. Started Nov 2024; status: recruiting.
02
Drugs
paclitaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06693336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06693336.